| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Thalidomide |
08.02.04 |
Formulary
|
NICE TA228: Multiple myeloma (first line) - bortezomib and thalidomide |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
| Docetaxel |
08.01.05 |
Restricted Use
|
CG 121 Lung Cancer |
| Irinotecan Hydrochloride |
08.01.05 |
Non Formulary
|
CG 131: Colorectal Cancer |
| Fluorouracil |
08.01.03 |
Formulary
|
CG 131: Colorectal Cancer |
| Celecoxib |
10.01.01 |
Formulary
|
CG 177: Osteoarthritis |
| Olanzapine |
04.02.01 |
Formulary
|
CG 178: Psychosis and schizophrenia in adults |
| Sorbsan ® Plus Border |
19.17 |
Formulary
|
CG 74: Surgical site infection: Prevention and treatment of surgical site infection |
| Sorbsan ® Packing |
19.17 |
Formulary
|
CG 74:Surgical site infection: Prevention and treatment of surgical site infection |
| Celecoxib |
10.01.01 |
Formulary
|
CG 79: Rheumatoid arthritis |
| Docetaxel |
08.01.05 |
Restricted Use
|
CG 81: Advanced Breast Cancer |
| Risperidone |
04.02.01 |
Formulary
|
CG178: Psychosis and schizophrenia in adults |
| Quetiapine |
04.02.01 |
Formulary
|
CG178: Psychosis and schizoprenia in adults |
| Atorvastatin |
02.12 |
Formulary
|
CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease |
| Pravastatin |
02.12 |
Formulary
|
CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease |
| Fluvastatin |
02.12 |
Non Formulary
|
CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease |
| Rosuvastatin |
02.12 |
Formulary
|
CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease |
| Simvastatin |
02.12 |
Formulary
|
CG181:Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease |
| Orlistat |
04.05.01 |
Formulary
|
CG43 Obesity: NICE guideline |
| Sorbsan ® Ribbon |
19.17 |
Formulary
|
CG74: Surgical site infection: Prevention and treatment of surgical site infection |
| Clopidogrel |
02.09 |
Formulary
|
CG94: Unstable angina and NSTEMI: The early management of unstable angina and non-ST-segment-elevation myocardial infarction |
| Triptorelin |
06.07.02 |
Formulary
|
CKS guideline: management of confirmed endometriosis - Secondary Care treatements |
| Triptorelin |
06.07.02 |
Formulary
|
CKS guideline: management of confirmed endometriosis - Secondary Care treatements |
| Leuprorelin |
06.07.02 |
Formulary
|
CKS guideline: Management of confirmed endometriosis - Secondary Care treatments |
| Leuprorelin |
06.07.02 |
Formulary
|
CKS guideline: Management of confirmed endometriosis - Secondary Care treatments |
| Goserelin |
06.07.02 |
Formulary
|
CKS guideline: Management of confirmed endometriosis- Secondary Care treatments |
| Ixazomib |
08.01.05 |
Restricted Use
|
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Gliclazide |
06.01.02.01 |
Formulary
|
NG28 :Type 2 diabetes in adults: management |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE 193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
| Flecainide |
02.03.02 |
Formulary
|
NICE Atrial fibrillation guidelines |
| Sotalol |
02.04 |
Formulary
|
NICE Atrial fibrillation guidelines |
| Amiodarone |
02.03.02 |
Formulary
|
NICE Atrial fibrillation guidelines |
| Propafenone |
02.03.02 |
Formulary
|
NICE Atrial fibrillation guidelines |
| Carbamazepine |
04.08.01 |
Formulary
|
NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Carbamazepine |
04.08.01 |
Formulary
|
NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Carbamazepine |
04.08.01 |
Formulary
|
NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Carbamazepine |
04.08.01 |
Formulary
|
NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Eslicarbazepine |
04.08.01 |
Formulary
|
NICE CG 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Capsaicin cream 0.025% |
10.03.02 |
Formulary
|
NICE CG 177 Osteoarthritis |
| Capecitabine |
08.01.03 |
Formulary
|
NICE CG 81: Advanced breast cancer (update): Diagnosis and treatment |
| Eplerenone |
02.02 |
Formulary
|
NICE CG108: Chronic heart failure in adults: management |
| Spironolactone |
02.02.03 |
Formulary
|
NICE CG108: Chronic heart failure in adults: management |
| Nutramigen® 1 with LGG (previous name Nutramigen® Lipil 1) |
09.04 |
Formulary
|
NICE CG116: Food allergy in under 19s: assessment and diagnosis |
| Nutramigen® 2 with LGG (previous name Nutramigen® Lipil 2) |
09.04 |
Formulary
|
NICE CG116: Food allergy in under 19s: assessment and diagnosis |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE CG121: Lung Cancer |
| Vinorelbine |
08.01.04 |
Formulary
|
NICE CG121: Lung cancer: diagnosis and management |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE CG121: Lung cancer: diagnosis and management |
| Nicorandil |
02.06 |
Formulary
|
NICE CG126: Stable angina: management |
| Ranolazine |
02.06 |
Formulary
|
NICE CG126: Stable angina: management |
| Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Stable angina: management |
| Oxaliplatin |
08.01.05 |
Non Formulary
|
NICE CG131: Colorectal cancer |
| Raltitrexed |
08.01.03 |
Formulary
|
NICE CG131: Colorectal cancer: diagnosis and management |
| Phenytoin |
04.08.01 |
Formulary
|
NICE CG137 The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Sodium valproate |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
| Sodium valproate |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
| Sodium valproate |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
| Levetiracetam |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
| Sodium Valproate |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
| Levetiracetam |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
| Levetiracetam |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
| Sodium valproate prolonged release |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
| Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Rufinamide |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Primidone |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Phenytoin |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Topiramate |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Lamotrigine |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Vigabatrin |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Zonisamide |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Oxcarbazepine |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Gabapentin |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Pregabalin |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Ethosuximide |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Phenobarbital |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Oxcarbazepine |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Phenobarbital |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Gabapentin |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Lamotrigine |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Calcipotriol 50micrograms/g with Betamethasone 0.05% |
13.05.02 |
Formulary
|
NICE CG153: Psoriasis: assessment and management |
| Buserelin |
06.07 |
Non Formulary
|
NICE CG156: Fertility problems: assessment and treatment |
| Phosphate supplements |
09.05.02.01 |
Formulary
|
NICE CG157: Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia |
| Ibuprofen |
10.01.01 |
Formulary
|
NICE CG160: Fever in under 5s: assessment and initial management |
| Anastrozole |
08.03.04.01 |
Formulary
|
NICE CG164: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - diagnosis and management |
| Tenofovir Disproxil |
05.03.01 |
Non Formulary
|
NICE CG165: Hepatitis B (chronic) - diagnosis and management |
| Adefovir Dipivoxil |
05.03.03 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - diagnosis and management |
| Entecavir |
05.03.03 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - diagnosis and management |
| Entecavir |
05.03.03 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - diagnosis and management |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic): diagnosis and management |
| Amitriptyline |
04.07.03 |
Formulary
|
NICE CG173: Neuropathic pain - pharmacological management in non-specialist settings |
| Amisulpride |
04.02.01 |
Formulary
|
NICE CG178: Psychosis and schizophrenia in adults |
| Digoxin |
02.01 |
Formulary
|
NICE CG180: Atrial fibrillation: management |
| Peptac |
01.01.02 |
Formulary
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
| Ranitidine |
01.03.01 |
Formulary
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
| Magnesium Trisilicate Mixture BP |
01.01.01 |
Formulary
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
| Ranitidine |
01.03.01 |
Formulary
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186: Multiple sclerosis in adults: management |
| Pabrinex |
09.06.02 |
Restricted Use
|
NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition |
| Vitamin B Tablets, Compound Strong |
09.06.02 |
Formulary
|
NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition |
| Valproic Acid |
04.02.03 |
Formulary
|
NICE CG38: Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care |
| Olanzapine |
04.02.01 |
Formulary
|
NICE CG38:Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care |
| Fosfomycin |
05.01.13 |
Formulary
|
NICE CG54: Urinary tract infection in under 16s: diagnosis and management |
| Peppermint Oil |
01.02 |
Formulary
|
NICE CG61 : Irritable bowel syndrome in adults: diagnosis and management |
| Hyoscine Butylbromide |
01.02 |
Formulary
|
NICE CG61: Irritable bowel syndrome in adults: diagnosis and management |
| Mebeverine Hydrochloride |
01.02 |
Formulary
|
NICE CG61: Irritable bowel syndrome in adults: diagnosis and management |
| Reteplase |
02.10 |
Restricted Use
|
NICE CG68: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management |
| Anastrozole |
08.03.04.01 |
Formulary
|
NICE CG80: Early and locally advanced breast cancer: diagnosis and treatment |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE CG81: Advanced Breast Cancer |
| Vinorelbine |
08.01.04 |
Formulary
|
NICE CG81: Advanced breast cancer: diagnosis and treatment |
| Exemestane |
08.03.04.01 |
Formulary
|
NICE CG81: Advanced breast cancer: diagnosis and treatment |
| Bivalirudin |
02.06 |
Formulary
|
NICE CG94: Unstable angina and NSTEMI; early management |
| Fosfomycin |
05.01.13 |
Formulary
|
NICE CG97: Lower urinary tract symptoms in men: management |
| Furosemide |
02.02.02 |
Formulary
|
NICE Chronic heart failure guidelines |
| Simeticone |
01.01.01 |
Formulary
|
NICE CKS Infantile colic |
| Doxylamine/pyridoxine |
04.06 |
Non Formulary
|
NICE ES20: Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy |
| Diltiazem Cream 2% |
01.07.04 |
Formulary
|
NICE evidence summary; Chronic anal fissure: 2% topical diltiazem hydrochloride |
| Eliglustat |
09.08.01 |
Formulary
|
NICE HST5: Eliglustat for treating type 1 Gaucher disease |
| Asfotase alfa |
09.08.01 |
Restricted Use
|
NICE HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia |
| Bendroflumethiazide |
02.02.01 |
Formulary
|
NICE Hypertension guidelines |
| Indapamide |
02.02.01 |
Formulary
|
NICE Hypertension guidelines |
| Chlortalidone |
02.02.01 |
Formulary
|
NICE Hypertension guidelines |
| Insulin Glargine |
06.01.01.02 |
Formulary
|
NICE NG17: Type 1 diabetes in adults: diagnosis and management |
| INSULIN GLARGINE |
06.01.01.02 |
Formulary
|
NICE NG17: Type 1 diabetes in adults: diagnosis and management |
| Insulin glargine |
06.01.01.02 |
Formulary
|
NICE NG17: Type 1 diabetes in adults: diagnosis and management |
| Insulin glargine 100units/ml |
06.01.01.02 |
Non Formulary
|
NICE NG17: Type 1 diabetes in adults: diagnosis and management |
| Metformin |
06.01.02.02 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management |
| Pioglitazone |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management |
| Metformin |
06.01.02.02 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management |
| Metformin |
06.01.02.02 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management |
| Metformin |
06.01.02.02 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management |
| Dulaglutide |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management (Dec 2015) |
| Exenatide |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management (Dec 2015) |
| Exenatide prolonged realease |
06.01.02.03 |
Non Formulary
|
NICE NG28: Type 2 diabetes in adults: management (Dec 2015) |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults: management (Dec 2015) |
| Glibenclamide |
06.01.02.01 |
Formulary
|
NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period |
| Capreomycin |
05.01.09 |
Formulary
|
NICE NG33: Tuberculosis |
| Deferiprone |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
| Desferrioxamine Mesilate |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
| Lisdexamphetamine |
04.04 |
Formulary
|
NICE NG87: Attention deficit hyperactivity disorder: diagnosis and management |
| Tinzaparin |
02.08.01 |
Formulary
|
NICE NG89: Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism |
| Memantine |
04.11 |
Formulary
|
NICE NG97: Dementia: assessment, management and support for people living with dementia and their carers |
| Rivastigmine |
04.11 |
Formulary
|
NICE NG97: Dementia: assessment, management and support for people living with dementia and their carers |
| Donepezil |
04.11 |
Formulary
|
NICE NG97: Dementia: assessment, management and support for people living with dementia and their carers |
| Galantamine |
04.11 |
Formulary
|
NICE NG97: Dementia: assessment, management and support for peop-le living with dementia and their carers |
| Apixaban |
02.08 |
Formulary
|
NICE Patient Decision Aid: Atrial Fibrillation: medicines to help reduce your risk of a stroke - what are the options? |
| Rivaroxaban |
02.08 |
Formulary
|
NICE Patient Decision Aid: Atrial Fibrillation: medicines to help reduce your risk of a stroke - what are the options? |
| Dabigatran |
02.08 |
Formulary
|
NICE Patient Decision Aid: Atrial Fibrillation: medicines to help reduce your risk of a stroke - what are the options? |
| Warfarin |
02.08 |
Formulary
|
NICE Patient Decision Aid: Atrial Fibrillation: medicines to help reduce your risk of a stroke - what are the options? |
| Raloxifene |
06.04.01.01 |
Formulary
|
NICE TA 160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA 253: Boceprevir for the treatment of genotype 1 chronic hepatitis C |
| Dimethyl fumarate |
08.02.04 |
Restricted Use
|
NICE TA 320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis |
| Golimumab |
01.05 |
Restricted Use
|
NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) |
| Rifaximin |
05.01.07 |
Formulary
|
NICE TA 337 :Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA 339: Omalizumab for previously treated chronic spontaneous urticaria |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA 340: Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313) |
| ROMOSOZUMAB |
06.06 |
Formulary
|
NICE TA 791: Romosozumab for treating severe osteoporosis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA:329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) |
| Oxaliplatin |
08.01.05 |
Non Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Docetaxel |
08.01.05 |
Restricted Use
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon alfa-2b |
08.02.04 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon Alfa |
05.03 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon Alfa |
05.03 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA108: Breast cancer (early) - paclitaxel |
| Docetaxel |
08.01.05 |
Restricted Use
|
NICE TA109: Breast cancer (early) - docetaxel |
| Anastrozole |
08.03.04.01 |
Formulary
|
NICE TA112: Breast cancer (early) - hormonal treatments |
| Exemestane |
08.03.04.01 |
Formulary
|
NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer |
| Letrozole |
08.03.04.01 |
Formulary
|
NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer |
| Buprenorphine |
04.10.03 |
Formulary
|
NICE TA114: Methadone and buprenorphine for the management of opioid dependence |
| Methadone |
04.10.03 |
Formulary
|
NICE TA114: Methadone and bupreorphine for the management of opioid dependence |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - Naltrexone for the management of opioid dependence |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Gemcitabine for the treatment of metastatic breast cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119:Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline for smoking cessation |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA124: Lung cancer (non-small-cell) - pemetrexed |
| Natalizumab |
08.02.04 |
Restricted Use
|
NICE TA127: Multiple sclerosis - natalizumab |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA130: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA137: Lymphoma (follicular non-Hodgkins) - rituximab |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA143: Adalimumab, etanercept and infliximab for ankylosing spondylitis |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Head and neck cancer - cetuximab |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA146 - Adalimumab for the treatment of adults with Psoriasis |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA146: Adalimumab for the treatment of adults with psoriasis |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA149: Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Entecavir for the treatment of chronic hepatitis B |
| Entecavir |
05.03.03 |
Formulary
|
NICE TA153: Entecavir for the treatment of chronic hepatitis B |
| Entecavir |
05.03.03 |
Formulary
|
NICE TA153: Entecavir for the treatment of chronic hepatitis B |
| Telbivudine |
05.03.03.01 |
Non Formulary
|
NICE TA154: Telbivudine for the treatment of chronic hepatitis B |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Pegaptanib Sodium |
11.08.02 |
Non Formulary
|
NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156: Routine antenatal anti-D prophylaxis for women who are rhesus D negative |
| Anti-D (Rh0) Immunoglobulin |
14.05 |
Formulary
|
NICE TA156: Routine antenatal anti-D prophylaxis for women who are rhesus D negative |
| Dabigatran |
02.08 |
Formulary
|
NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
| Etidronate disodium |
06.06.02 |
Formulary
|
NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Etidronate disodium |
06.06.02 |
Formulary
|
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Calcitonin (salmon) / Salcatonin |
06.06.01 |
Formulary
|
NICE TA161: Osteoporosis - secondary prevention (including strontium ranelate) |
| Teriparatide |
06.06 |
Formulary
|
NICE TA161: Osteoporosis - secondary prevention (including Teriparatide) |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Febuxostat |
10.01.04 |
Formulary
|
NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA165: Hepatitis B (chronic): Diagnosis and management of chronic hepatitis B in children, young people and adults |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Rivaroxaban |
02.08 |
Formulary
|
NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA171: Multiple myeloma - lenalidomide |
| Tenofovir Disproxil |
05.03.01 |
Non Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab |
| Oxaliplatin |
08.01.05 |
Non Formulary
|
NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer |
| Alitretinoin |
13.05.01 |
Formulary
|
NICE TA177: Eczema (chronic) - alitretinoin |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA178: Renal cell carcinoma |
| Temsirolimus |
08.01.05 |
Formulary
|
NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Cisplatin |
08.01.05 |
Formulary
|
NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer |
| Prasugrel |
02.09 |
Formulary
|
NICE TA182: Prasugrel for the treatment of acute coronary syndromes with percutaneous cornonary intervention |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Cisplatin |
08.01.05 |
Formulary
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer |
| Topotecan |
08.01.05 |
Restricted Use
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Topotecan |
08.01.05 |
Restricted Use
|
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA186: Certolizumab pegol for the treatment of rheumatoid arthritis |
| Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40) |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40) |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA187: Infliximab (review) and adalimumab for the treatment of Crohns disease |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review) |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Rituximab (rheumatology) |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Interferon alfa-2b |
08.02.04 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon alfa-2b |
08.02.04 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
05.03 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
05.03 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA202: Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA203: Diabetes (type 2) - liraglutide |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA206: Bendamustine for the treatment of indolent (low grade) non-Hodgkins lymphoma that is refractory to rituximab (terminated appraisal) |
| Temsirolimus |
08.01.05 |
Formulary
|
NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Cisplatin |
08.01.05 |
Formulary
|
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Prucalopride for the treatment of chronic constipation in women |
| Oxaliplatin |
08.01.05 |
Non Formulary
|
NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer |
| Fluorouracil |
08.01.03 |
Formulary
|
NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years (NICE TA 213) |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer |
| Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
| Galantamine |
04.11 |
Formulary
|
NICE TA217: Alzheimers disease |
| Galantamine |
04.11 |
Formulary
|
NICE TA217: Alzheimers disease |
| Rivastigmine |
04.11 |
Formulary
|
NICE TA217: Alzheimers disease |
| Galantamine |
04.11 |
Formulary
|
NICE TA217: Alzheimers disease |
| Donepezil |
04.11 |
Formulary
|
NICE TA217: Alzheimers disease |
| Rivastigmine |
04.11 |
Formulary
|
NICE TA217: Alzheimers disease |
| Donepezil |
04.11 |
Formulary
|
NICE TA217: Alzheimers disease |
| Memantine |
04.11 |
Formulary
|
NICE TA217: Alzheimers disease |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA220: Psoriatic arthritis - golimumab |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA222- ovarian cancer |
| Naftidrofuryl Oxalate |
02.06.04 |
Formulary
|
NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA225: Rheumatoid arthritis - golimumab |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkins lymphoma |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer |
| Thalidomide |
08.02.04 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228:Bortezomib and thalidomide for the first-line treatment of multiple myeloma |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema |
| Dexamethasone 700mcg |
11.04.01 |
Restricted Use
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Brain cancer - temozolomide |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Retigabine |
04.08.01 |
Non Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Mifamurtide |
08.02.04 |
Formulary
|
NICE TA235: Mifamurtide for the treatment of osteosarcoma |
| Mifamurtide |
08.02.04 |
Restricted Use
|
NICE TA235: Mifamurtide for the treatment of osteosarcoma |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236 Ticagrelor for the treatment of acute coronary syndromes |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA238: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma: (review of NICE technology appraisal guidance 110) |
| Apixaban |
02.08 |
Formulary
|
NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Bee and Wasp Allergen Extracts |
03.04 |
Formulary
|
NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198) |
| Dabigatran |
02.08 |
Formulary
|
NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA25: Guidance on the use of gemcitabine for the treatment of pancreatic cancer |
| Telaprevir |
05.03.03.02 |
Formulary
|
NICE TA252: Telaprevir for the treatment of genotype 1 chronic hepatitis C |
| Telaprevir |
05.03.03 |
Formulary
|
NICE TA252: Telaprevir for the treatment of genotype 1 chronic hepatitis C |
| Boceprevir |
05.03.03.02 |
Formulary
|
NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fingolimod |
08.02.04 |
Restricted Use
|
NICE TA254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis |
| Rivaroxaban |
02.08 |
Formulary
|
NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Lapatinib |
08.01.05 |
Formulary
|
NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Botulinum Toxin Type A |
04.07.04.02 |
Formulary
|
NICE TA260: Botox for migraine prophylaxis |
| Rivaroxaban |
02.08 |
Formulary
|
NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer |
| Alteplase |
02.10 |
Formulary
|
NICE TA264: Alteplase for treating acute ischaemic stroke |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance (TA265 ) |
| Mannitol inhalation |
03.07 |
Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation (TA266) |
| Ivabradine |
02.06.03 |
Formulary
|
NICE TA267: Ivabradine for treating chronic heart failure |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: pilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma |
Decitabine |
08.01.03 |
Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270) |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272) |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA274: Ranibizumab for treating diabetic macular oedema |
| Apixaban |
02.08 |
Formulary
|
NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) |
| Colistimethate Inhaler |
05.01.07 |
Formulary
|
NICE TA276: Colistimethate sodium and tobromycin dry powder for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Tobramycin |
05.01.04 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276) |
| Omalizumab |
03.14 |
Formulary
|
NICE TA278: Omalizumab for treating severe persistent allergic asthma |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA280: Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (2nd line) (rapid review of TA234) |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA280: Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234) |
| pirfenidone |
17 |
Non Formulary
|
NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone (TA282) |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
| Carboplatin |
08.01.05 |
Non Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer |
| Carboplatin |
08.01.05 |
Non Formulary
|
NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer |
| Rivaroxaban |
02.08 |
Formulary
|
NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration |
| Ocriplasmin |
11.08.02 |
Restricted Use
|
NICE TA297: Ocriplasmin for treating vitreomacular traction |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
| Peginterferon alfa-2b |
08.02.04 |
Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Peginterferon Alfa |
05.03 |
Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Peginterferon Alfa |
05.03 |
Formulary
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA301: Diabetic macular oedema - fluocinolone acetonide intravitreal implant (TA271) |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
| Teriflunomide |
08.02.04 |
Restricted Use
|
NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis |
| Teriflunomide |
08.02.04 |
Restricted Use
|
NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Pixantrone |
08.01.05 |
Restricted Use
|
NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkins B‑cell lymphoma |
| Aflibercept |
08.01.05 |
Non Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Rituximab (rheumatology) |
10.01.03 |
Restricted Use
|
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA309: Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: pilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Nalmefene |
04.10.01 |
Restricted Use
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Dabigatran |
02.08 |
Formulary
|
NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Infliximab |
01.05.03 |
Restricted Use
|
NICE TA329: Infiximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Adalimumab |
01.05.03 |
Restricted Use
|
NICE TA329:Infliximab,adalimumab,and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Rivaroxaban |
02.08 |
Formulary
|
NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (March 2015) |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes |
| Rifaximin |
01.09 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Omalizumab |
13.05.03 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab |
03.14 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA34: Advanced breast cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer |
| Apixaban |
02.08 |
Formulary
|
NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Vedolizumab |
01.05.03 |
Restricted Use
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia |
| Chlorambucil |
08.01.01 |
Formulary
|
NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia |
| Chlorambucil |
08.01.01 |
Formulary
|
NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
| Naloxegol |
01.06.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid‑induced constipation |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA346: Aflibercept for treating diabetic macular oedema |
| Nintedanib |
03.11 |
Formulary
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
| Dexamethasone 700mcg |
11.04.01 |
Restricted Use
|
NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis |
| Vedolizumab |
01.05.03 |
Restricted Use
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Edoxaban |
02.08 |
Formulary
|
NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
| Edoxaban |
02.08 |
Formulary
|
NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358:Tolvaptan for treating autosomal dominant polycystic kidney disease |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia |
| Ledipasvir/sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Daclatasvir |
05.03.03.02 |
Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Ombitasvir-paritaprevir-ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Vortioxetine |
04.03.03 |
Formulary
|
NICE TA367: Vortioxetine for treating major depressive episodes (Nov 2015) |
| Ciclosporin 1mg/mL |
11.99.99.99 |
Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Enzalutamide |
08.03.04.02 |
Restricted Use
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Nintedanib |
03.11 |
Restricted Use
|
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis |
| Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA383:TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383:TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
| Ruxolitinib |
08.01.05 |
Non Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Ruloxitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Sacubitril valsartan |
02.05.05 |
Formulary
|
NICE TA388:Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
| Doxorubicin Hydrochloride |
08.01.02 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Topotecan |
08.01.05 |
Restricted Use
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA389:Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Cabazitaxel |
08.01.05 |
Restricted Use
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxe |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Lumacaftor with ivacaftor |
03.07 |
Formulary
|
NICE TA398: Lumacaftor-ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Bosutinib |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Trifluridine-tipiracil |
08.01.03 |
Formulary
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Pegaspargase |
08.01.05 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Talimogene Iaherparepvec |
08.01.05 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Radium-223 |
16.01 |
Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Radium-223 |
16.01 |
Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Radium-223 |
16.06 |
Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Osimertinib |
08.01.05 |
Formulary
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428:Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Sofosbuvir/velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Mepolizumab |
03.14 |
Formulary
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis |
| Obeticholic acid |
01.09 |
Formulary
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphomaBrentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Etelcalcetide |
09.05.01.02 |
Formulary
|
NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Blinatumomab |
08.02.03 |
Formulary
|
NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Ponatinib |
08.01.05 |
Formulary
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Ponatinib |
08.01.05 |
Formulary
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Ustekinumab |
01.05 |
Restricted Use
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Carfilzomib |
08.01.05 |
Restricted Use
|
NICE TA457: Carfilzomib for previously treated multiple myeloma |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
| Collagenase clostridium histolyticum |
10.03.01 |
Formulary
|
NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Adalimumab |
11.99.99.99 |
Formulary
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Dexamethasone 700mcg |
11.04.01 |
Restricted Use
|
NICE TA460: https://www.nice.org.uk/guidance/ta460 |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma |
| Ibandronic acid |
06.06 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Risedronate Sodium |
06.06.02 |
Non Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Alendronic Acid |
06.06 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Zoledronic acid |
06.06 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Alendronic acid |
06.06.02 |
Formulary
|
NICE TA464:Bisphosphonates for treating osteoporosis |
| Olaratumab |
08.01.05 |
Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
| Doxorubicin Hydrochloride |
08.01.02 |
Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA470: Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) |
| Eluxadoline |
01.02 |
Non Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
| Dimethyl fumarate |
13.05.03 |
Formulary
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Paclitaxel albumin-bound |
08.01.05 |
Restricted Use
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Reslizumab |
03.14 |
Formulary
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Reslizumab |
03.04.02 |
Formulary
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Everolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Belatacept |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Anti-human thymocyte immunoglobulin (rabbit) |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Mycophenolate Sodium |
08.02.01 |
Non Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Mycophenolate Mofetil |
08.02.01 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA481:Immunosuppressive therapy for kidney transplant in adults |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Mycophenolate Mofetil |
08.02.01 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Mycophenolate Sodium |
08.02.01 |
Non Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Anti-human thymocyte immunoglobulin (rabbit) |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Belatacept |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Everolimus |
08.02.02 |
Formulary
|
NICE TA482:Immunosuppressive therapy for kidney transplant in children and young people |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer |
| Sarilumab |
08.02.04 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA486: Aflibercept for treating choroidal neovascularisation |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Cladribine |
08.02.04 |
Formulary
|
NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis |
| Naltrexone-bupropion |
04.05.02 |
Non Formulary
|
NICE TA494: Naltrexone-bupropion for managing overweight and obesity |
| Palbociclib |
08.01.05 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Ribociclib |
08.01.05 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Midostaurin |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Glecaprevir-pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer |
| Pirfenidone |
03.11 |
Restricted Use
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Ixazomib |
08.01.05 |
Formulary
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Sofosbuvir/Velpatasvir/Voxilaprevir |
05.03.03.02 |
Formulary
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Brodalumab |
10.01.03 |
Formulary
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Brodalumab |
10.01.03 |
Restricted Use
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Brodalumab |
13.05.02 |
Restricted Use
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Tivozanib |
08.01.05 |
Formulary
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen |
| Avelumab |
10.01.03 |
Restricted Use
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma |
| Avelumab |
10.01.03 |
Restricted Use
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma |
| Avelumab |
08.02.03 |
Formulary
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA519: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Urokinase |
02.10 |
Formulary
|
NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
| Cytarabine-Daunorubicin Liposomal |
08.01.03 |
Formulary
|
NICE TA522: Liposomal cytatabine-daunorubicin for untreated acute myeloid leukaemia |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Midostaurin |
08.01.05 |
Formulary
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia |
| Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia |
| Interferon beta-1a |
08.02.04 |
Non Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta-1b |
08.02.04 |
Non Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Niraparib |
08.01.05 |
Formulary
|
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Cenegermin |
08.01.05 |
Formulary
|
NICE TA532: Cenegermin for treating neurotrophic keratitis |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA533: Ocrelizumab for treating relapsing-remitting multiple sclerosis |
| Dupilumab |
08.01.05 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Alectinib |
08.01.05 |
Formulary
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Dinutuximab |
08.02.03 |
Formulary
|
NICE TA538: Dinutuximab beta for treating neuroblastoma |
| Lutetium (177Lu) oxodotreotide |
08.03.04.03 |
Formulary
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Inotuzumab ozogamicin |
08.02.03 |
Formulary
|
NICE TA541: Inotuzumab ozogamicin for treating relpased or refractory B-cell acute lymphoblastic leukaemia |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Dabrafenib with trametinib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Dabrafenib with Trametinib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Gemtuzumab ozogamicin |
08.02.03 |
Formulary
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Padeliporfin |
08.02 |
Non Formulary
|
NICE TA546: Padeliporfin for untreated localised prostate cancer |
| Tofacitinib |
01.05.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Carboplatin |
08.01.05 |
Non Formulary
|
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer |
| Cisplatin |
08.01.05 |
Formulary
|
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA55: Ovarian cancer - paclitaxel (review) |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence |
| Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA554: Tisagenlecleucel for treating relpased or refactory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph mode involvement or metastatic disease |
| Axicabtagene ciloleucel |
08.02.04 |
Formulary
|
NICE TA559: Axicabtagene ciloleucel for treating large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Encorafenib with binimetinib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation - positive melanoma |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Benralizumab |
03.14 |
Formulary
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
| Benralizumab |
03.04.02 |
Formulary
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
| Cochlear implants |
12.01.01 |
Formulary
|
NICE TA566: Cochlear implants for children and adults with severe to profound deafness |
| Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Brigatinib |
08.01.05 |
Formulary
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
| Nusinersen |
10.02 |
Formulary
|
NICE TA588: Nusinersen for treating spinal muscular atrophy |
| Blinatumomab |
08.02.03 |
Formulary
|
NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Letermovir |
05.03.02.02 |
Formulary
|
NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
| Cemiplimab |
08.01.05 |
Formulary
|
NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma |
| Ribociclib |
08.01.05 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA594: Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA594; Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) |
| Dacomitinib |
08.01.05 |
Formulary
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Risankizumab |
13.05.02 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
| Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Botulinum neurotoxin type A |
04.12 |
Formulary
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
| Lanadelumab |
03.04.03 |
Formulary
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
| Rivaroxaban |
02.08 |
Formulary
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA61: Colorectal cancer - capecitabine and tegafur uracil |
| Pentosan polysulfate sodium |
07.04.03 |
Formulary
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome |
| Rucaparib |
08.01.05 |
Formulary
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Neratinib |
08.01.05 |
Formulary
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
| Cladribine |
08.02.04 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
| Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Palbociclib |
08.01.05 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Sotagliflozin |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
| Patiromer |
09.02.01.01 |
Formulary
|
NICE TA623: Patiromer for treating hyperkalaemia |
| Peginterferon beta-1a |
08.02.04 |
Formulary
|
NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
| Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Lorlatinib |
08.01.05 |
Formulary
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Larotrectinib |
08.01.05 |
Formulary
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631: Fremanezumab for preventing migraine |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
| Ustekinumab |
01.05 |
Restricted Use
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) - human growth hormone |
| Treosulfan |
08.01.01 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
| Gilteritinib |
08.01.05 |
Formulary
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
| Entrectinib |
08.01.05 |
Formulary
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Entrectinib |
08.01.05 |
Formulary
|
NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours |
| Avelumab |
08.02.03 |
Formulary
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Avelumab |
10.01.03 |
Restricted Use
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Naldemedine |
01.06.06 |
Formulary
|
NICE TA6451: Naldemedine for treating opioid-induced constipation |
| Polatuzumab |
08.01.05 |
Formulary
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA65: Rituximab for aggressive non-Hodgkins lymphoma |
| Osimertinib |
08.01.05 |
Formulary
|
NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
| Osimertinib |
08.01.05 |
Formulary
|
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy |
| Siponimod |
08.02.04 |
Formulary
|
NICE TA656: Siponimod for treating secondary progressive multiple sclerosis |
| Carfilzomib |
08.01.05 |
Restricted Use
|
NICE TA657: Carfilzomib for previously treated multiple myeloma |
| Isatuximab |
08.01.05 |
Formulary
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma |
| Galcanezumab |
04.07.04.02 |
Formulary
|
NICE TA659: Galcanezumab for preventing migraine |
| Darolutamide |
08.03.04.02 |
Formulary
|
NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA664: Liraglutide for managing overweight and obesity |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA664: Liraglutide for managing overweight and obesity |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA665: Upadacitinib for treating severe rheumatoid arthritis |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma |
| Caplacizumab |
09.01.04 |
Formulary
|
NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura |
| Encorafenib plus cetuximab |
08.01.05 |
Formulary
|
NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer |
| Brigatinib |
08.01.05 |
Formulary
|
NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor |
| Mepolizumab |
03.14 |
Formulary
|
NICE TA671: Mepolizumab for treating severe eosinophilic asthma |
| Brolucizumab |
11.08.02 |
Formulary
|
NICE TA672: Brolucizumab for treating wet age-related macular degeneration |
| Niraparib |
08.01.05 |
Formulary
|
NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy |
| Filgotinib |
10.01.03 |
Formulary
|
NICE TA676: Filgotinib for treating moderate to severe rheumatoid arthritis |
| Autologous anti-CD19-transduced CD3+ cells |
08.01.05 |
Formulary
|
NICE TA677: Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction |
| Verteporfin |
11.08.02 |
Restricted Use
|
NICE TA68: Guidance on the use of photodynamic therapy (PDT) for age-related macular degeneration (ARMD) |
| Lenalidomide |
08.02.04 |
Restricted Use
|
NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma |
| Baricitinib |
13.05.03 |
Formulary
|
NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis |
| Erenumab |
04.07.04.02 |
Formulary
|
NICE TA682: Erenumab for preventing migraine |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
| Anakinra |
10.01.03 |
Restricted Use
|
NICE TA685: Anakinra for treating Still’s disease |
| Ribociclib |
08.01.05 |
Formulary
|
NICE TA687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Selective internal radiation therapies |
08.04 |
Formulary
|
NICE TA688: Selective internal radiation therapies for treating hepatocellular carcinoma |
| Acalabrutinib |
08.01.05 |
Formulary
|
NICE TA689: Acalabrutinib for treating chronic lymphocytic leukaemia |
| Avelumab |
08.02.03 |
Formulary
|
NICE TA691: Avelumab for untreated metastatic Merkel cell carcinoma |
| Avelumab |
10.01.03 |
Restricted Use
|
NICE TA691: Avelumab for untreated metastatic Merkel cell carcinoma |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA693: Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer |
| Bempedoic acid with ezetimibe |
02.12 |
Formulary
|
NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia |
| Carfilzomib |
08.01.05 |
Restricted Use
|
NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma |
| Andexanet alfa |
18 |
Formulary
|
NICE TA697: Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban |
| Ravulizumab |
09.01.03 |
Formulary
|
NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA699: Ofatumumab for treating relapsing multiple sclerosis |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA70: Leukaemia (chronic myeloid) - imatinib |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer |
| Budesonide |
01.05.02 |
Formulary
|
NICE TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency |
| Ravulizumab |
09.01.03 |
Formulary
|
NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA711: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Enzalutamide |
08.03.04.02 |
Restricted Use
|
NICE TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA718: Ixekizumab for treating axial spondyloarthritis |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA719: Secukinumab for treating non-radiographic axial spondyloarthritis |
| Chlormethine gel |
08.01.05 |
Formulary
|
NICE TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma |
| Pemigatinib |
08.01.05 |
Formulary
|
NICE TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement |
| Bimekizumab |
13.05.02 |
Formulary
|
NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA725: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Midostaurin |
08.01.05 |
Formulary
|
NICE TA728: Midostaurin for treating advanced systemic mastocytosis |
| Sapropterin Dihydrochloride |
09.04.01 |
Formulary
|
NICE TA729: Sapropterin for treating hyperphenylalaninaemia in phenylketonuria |
| Inclisiran |
02.12 |
Formulary
|
NICE TA733: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer |
| Berotralstat |
03.04.03 |
Formulary
|
NICE TA738:Berotralstat for preventing recurrent attacks of hereditary angioedema |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable |
| Apalutamide |
08.03.04.02 |
Formulary
|
NICE TA740: Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer |
| Apalutamide |
08.03.04.02 |
Formulary
|
NICE TA741: Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer |
| Selpercatinib |
08.01.05 |
Formulary
|
NICE TA742: Selpercatinib for treating advanced thyroid cancer with RET alterations |
| Crizanlizumab |
08.01.05 |
Formulary
|
NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA746: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer |
| Nintedanib |
03.11 |
Restricted Use
|
NICE TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases |
|
02.03.02 |
Formulary
|
NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders |
| Mexiletine 167mg hard capsules |
10.02.02 |
Formulary
|
NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Interferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Interferon gamma-1b |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon alfa-2b |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
05.03 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
05.03 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Dupilumab |
08.01.05 |
Formulary
|
NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation |
| Dupilumab |
03.04.03 |
Formulary
|
NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation |
| Belimumab |
08.01.05 |
Formulary
|
NICE TA752: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Cenobamate |
04.08.01 |
Formulary
|
NICE TA753: Cenobamate for treating focal onset seizures in epilepsy |
| Mogamulizumab |
08.01.05 |
Formulary
|
NICE TA754: Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome |
| Risdiplam |
10.02 |
Formulary
|
NICE TA755: Risdiplam for treating spinal muscular atrophy |
| Fedratinib |
08.01.05 |
Formulary
|
NICE TA756: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis |
| Cabotegravir |
05.03.01 |
Formulary
|
NICE TA757: Cabotegravir with rilpivirine for treating HIV-1 |
| Solriamfetol |
04.04 |
Formulary
|
NICE TA758: Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy |
| Selpercatinib |
08.01.05 |
Formulary
|
NICE TA760: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer |
| Osimertinib |
08.01.05 |
Formulary
|
NICE TA761: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA763: Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable |
| Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA764: Fremanezumab for preventing migraine |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA765: Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma |
| Ponesimod |
08.02.04 |
Formulary
|
NICE TA767: Ponesimod for treating relapsing–remitting multiple sclerosis |
| Upadacitinib |
10.01.03 |
Formulary
|
NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Palforzia® |
03.04.02 |
Formulary
|
NICE TA769: Palforzia for treating peanut allergy in children and young people |
| Zolpidem |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA775: Dapagliflozin for treating chronic kidney disease |
| Pegcetacoplan |
08.01.05 |
Formulary
|
NICE TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria |
| Dostarlimab |
08.01.05 |
Formulary
|
NICE TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Sotorasib |
08.01.05 |
Formulary
|
NICE TA781: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA783: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Niraparib |
08.01.05 |
Formulary
|
NICE TA784: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
| Tucatinib |
08.01.05 |
Formulary
|
NICE TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable |
| Avelumab |
08.02.03 |
Formulary
|
NICE TA788: Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy |
| Tepotinib |
08.01.05 |
Formulary
|
NICE TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations |
| Icosapent ethyl |
02.12 |
Formulary
|
NICE TA805 :Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides |
| Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib |
| Doxorubicin Hydrochloride |
08.01.02 |
Formulary
|
NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) |
| Carboplatin |
08.01.05 |
Non Formulary
|
NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer |
| Cisplatin |
08.01.05 |
Formulary
|
NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer |
| Paclitaxel |
08.01.05 |
Restricted Use
|
NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer: |
| Adefovir Dipivoxil |
05.03.03 |
Formulary
|
NICE TA96: Adefovir dipivoxil and peginterfeon alfa-2a for the treatment of chronic hepatitis B |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B |
| Methylphenidate |
04.04 |
Formulary
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Methylphenidate |
04.04 |
Formulary
|
NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Modafinil |
04.04 |
Formulary
|
NICE: Evidence Summary (Apr 2013) |
| MIDODRINE Tablets 2.5 mg, 5mg |
20 |
Non Formulary
|
NICE: Postural hypotension in adults: midodrine (ESUOM5) |
| Domperidone |
04.06 |
Formulary
|
NICE: Promoting tolerance of enteral feeds in children and young people: domperidone |
| Domperidone |
04.06 |
Formulary
|
NICE: Promoting tolerance of enteral feeds in children and young people: domperidone |
| Domperidone |
04.06 |
Formulary
|
NICE: Promoting tolerance of enteral feeds in children and young people: domperidone |
| Domperidone |
01.02 |
Formulary
|
NICE: Promoting tolerance of enteral feeds in children and young people: domperidone |
| Bupropion Hydrochloride |
04.10.02 |
Formulary
|
NICE: Smoking cessation services |
| Nicotine replacement therapy |
04.10.02 |
Formulary
|
NICE: Smoking cessation services |
| Fluorouracil |
08.01.03 |
Formulary
|
TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer |
| Risedronate Sodium |
06.06.02 |
Non Formulary
|
TA 161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended) |
| Zanamivir |
05.03.04 |
Formulary
|
TA 168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Irinotecan Hydrochloride |
08.01.05 |
Non Formulary
|
TA 176: Cetuximab for the first-line treatment of metastatic colorectal cancer |
| Cyclophosphamide |
08.01.01 |
Formulary
|
TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer |
| Doxorubicin Hydrochloride |
08.01.02 |
Formulary
|
TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer |
| Irinotecan Hydrochloride |
08.01.05 |
Non Formulary
|
TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer |
| Oseltamivir |
05.03.04 |
Formulary
|
TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Zanamivir |
05.03.04 |
Formulary
|
TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Oseltamivir |
05.03.04 |
Formulary
|
TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Risedronate Sodium |
06.06.02 |
Non Formulary
|
TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) |
| Alendronic Acid |
06.06 |
Formulary
|
TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) |
| Alendronic Acid |
06.06 |
Formulary
|
TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended) |
| Oseltamivir |
05.03.04 |
Formulary
|
TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Oseltamivir |
05.03.04 |
Formulary
|
TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Cyclophosphamide |
08.01.01 |
Formulary
|
TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
| Fluorouracil |
08.01.03 |
Formulary
|
TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer |
| Sorafenib |
08.01.05 |
Formulary
|
TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma |
| Cyclophosphamide |
08.01.01 |
Formulary
|
TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
| Capecitabine |
08.01.03 |
Formulary
|
TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
| Fluorouracil |
08.01.03 |
Formulary
|
TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
| Clopidogrel |
02.09 |
Formulary
|
TA210: clopidogrel and m/r dipyridamole in the prevention of occlusive vascular events |
| Aspirin (antiplatelet) |
02.09 |
Formulary
|
TA210: Modified release dipyridamole in combination with aspirin |
| Doxorubicin Hydrochloride |
08.01.02 |
Formulary
|
TA222: Trabectedin for the treatment of relapsed ovarian cancer |
| Agomelatine |
04.03.04 |
Formulary
|
TA231: Agomelatine for the treatment of major depressive episodes (terminated appraisal) |
| Aspirin (antiplatelet) |
02.09 |
Formulary
|
TA236: Ticagrelor with low dose aspirin for the treatment of acute coronary syndromes |
| Irinotecan Hydrochloride |
08.01.05 |
Non Formulary
|
TA242: Metastatic colorectal cancer after first-line chemotherapy |
| Capecitabine |
08.01.03 |
Formulary
|
TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer |
| Mannitol |
03.07 |
Restricted Use
|
TA266: Mannitol dry powder for inhalation for treating cystic fibrosis |
| Omalizumab |
03.04.02 |
Restricted Use
|
TA278 Asthma (severe, persistent, patients aged 6+,adults) - omalizumab (revised TA133, TA201) |
| Canakinumab |
08.02.04 |
Non Formulary
|
TA281: terminated appriasal: Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) |
| Docetaxel |
08.01.05 |
Restricted Use
|
TA30: Taxanes for the treatment of Breast Cancer |
| Canakinumab |
08.02.04 |
Non Formulary
|
TA302: terminated appraisal: Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) |
| Irinotecan Hydrochloride |
08.01.05 |
Non Formulary
|
TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Fluorouracil |
08.01.03 |
Formulary
|
TA307:Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Alemtuzumab |
08.02.03 |
Formulary
|
TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis |
| Ustekinumab |
13.05.03 |
Formulary
|
TA313: Ustekinumab for treating active psoriatic arthritis |
| Pioglitazone |
06.01.02.03 |
Non Formulary
|
TA63: Glitazones in the treatment of type 2 diabetes (Review of TA9 and TA21) |
| Clopidogrel |
02.09 |
Formulary
|
TA80: Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome |
| Fludroxycortide tape |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Flucinolone Acetonide 0.025% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Flucinolone Acetonide 0.0025% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| fluocinolone acetonide 0.025% with clioquinol 3% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Mometasone Furoate 0.1% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Hydrocortisone Butyrate 0.1% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Betamethasone (as Valerate) 0.1% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Betamethasone (as Valerate) 0.025% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Betamethasone (as Dipropionate) 0.05% with Salicylic Acid |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Betamethasone Dipropionate 0.064% with Clotrimazole 1% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Clobetasol Propionate 0.05% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Hydrocortisone 0.25% Crotamiton 10% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Hydrocortisone 1% with Clotrimazole 1% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Hydrocortisone 1% with Miconazole Nitrate 2% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Hydrocortisone Acetate 1% with Fusidic Acid 2% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Hydrocortisone 0.5% ,chlorhexidine HCl 1% & nystatin |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Clobetasone Butyrate 0.05% |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Trimovate® |
13.04 |
Formulary
|
TA81: Frequency of application of topical corticosteroids for atopic eczema |
| Atomoxetine |
04.04 |
Formulary
|
TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
| Dexamfetamine |
04.04 |
Formulary
|
TA98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
